RENT.COM.AU LIMITED — Capital/Financing Update 2007

Apr 18, 2007

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003.

Name of entity

Select Vaccines Limited

ABN

25 062 063 692

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

$\mathbf{1}$ ⁺Class of ⁺securities issued or to be issued

Ordinary shares

29,518,072

• $\mathcal{I}$ Number of ⁺securities issued or to be issued (if known) or maximum number which may be issued
• $\overline{3}$ Principal terms of the ⁺securities (eg, if options, exercise price and partly date; $if$ expiry paid *securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

In accordance with Clause 4.1 of the Collaboration and Licensing Agreement with AVANT Immunotherapeutics, Inc. dated 9 February 2007.

4	Do the securities rank equally in all respects from the date of allotment with an existing "class of quoted securities? If the additional securities do not rank equally, please state: the date from which they do which the extent to. they participate for the next dividend, οf case (in the a trust. distribution) or interest payment the extent to which they do not ۰ rank equally, other than in relation to the next dividend, distribution or interest payment	Yes
5.	Issue price or consideration	\$0.02965 per share
6.	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	To finance research and development and to provide working capital
7	Dates of entering "securities into uncertificated holdings or despatch of certificates	Thursday 19 April 2007
8	all Number and class of securities quoted on on ASX. (including the securities in clause 2 if applicable)	Number 255,350,452 23,479,265	+ Class Ordinary Fully Paid Options ex 20cents 31/5/08

⁺ See chapter 19 for defined terms.

		Number	+ Class
9	aIl Number class οf and securities not quoted on ASX (including the securities in clause 2 if applicable)	3,520,000	Options 30cents SLTAO
		500,000	Options 30cents SLTAQ
		1,500,000	Options 30cents SLTAP
		2,000,000	Options 44 cents SLTAS
		1,000,000	Options 44 cents SLTAU
		3,000,000	Options 0 cents

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

	,我们也不会不会不会。""我们的,我们也不会不会不会。""我们的,我们也不会不会不会不会。""我们的,我们也不会不会不会不会。""我们的,我们也不会不会不会不会
,我们也不会有一个人的事情。""我们的人们,我们也不会有一个人的人,我们也不会有一个人的人,我们也不会有一个人的人,我们也不会有一个人的人,我们也不会有一个人的 第一百一十一章 我们的人,我们的人们的人们,我们的人们的人们的人们,我们的人们的人们的人们,我们的人们的人们,我们的人们的人们,我们的人们的人们,我们的人们的人

Part 2 - Bonus issue or pro rata issue- $N/A$

• $11$ $Is$ security holder approval required?
• $12^°$ Is the issue renounceable or nonrenounceable?
• 13 Ratio in which the "securities will be offered
• $14$ ^*Class of ^*securities to which the offer relates
• 15 *Record date $\mathbf{t}$ determine entitlements
• 16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?
• Policy for deciding entitlements in 17 relation to fractions
• Names of countries in which the 18 entity has *security holders who will not be sent new issue documents

Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.

19 Closing date for receipt of acceptances or renunciations

⁺ See chapter 19 for defined terms.

Appendix 3B New issue announcement

20	Names of any underwriters
21	Amount of any underwriting fee or commission
22	Names of any brokers to the issue
23	Fee or commission payable to the broker to the issue
24	any handling Amount of fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders
25.	If the issue is contingent on *security holders' approval, the date of the meeting
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
28	Date rights trading will begin (if applicable)
29	Date rights trading will end (if applicable)
30	How do *security holders sell their entitlements in full through a broker?
31	How do *security holders sell part of their entitlements through a broker and accept for the balance?

32 How do *security holders dispose of their entitlements (except by sale through a broker)?

33 ⁺Despatch date

Part 3 - Ouotation of securities

You need only complete this section if you are applying for quotation of securities

• 34 Type of securities (tick one)
• Securities described in Part 1 $(a)$
• All other securities $(b)$

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

• If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
• 36 If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories $1 - 1.000$ $1,001 - 5,000$ $5,001 - 10,000$ $10,001 - 100,000$ 100,001 and over

37

35

A copy of any trust deed for the additional *securities

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38.	Number of securities for which *quotation is sought	29,518,072
39.	Class of "securities for which quotation is sought	Ordinary Fully Paid
40	Do the securities rank equally in all respects from the date of allotment with an existing "class of quoted securities?	Yes
	If the additional securities do not rank equally, please state: the date from which they do which the extent to they $\bullet$ participate for the next dividend, the case (in οf trust. a distribution) or interest payment the extent to which they do not $\bullet$ rank equally, other than in relation to the next dividend, distribution or interest payment
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period	Per Collaboration and Licensing Agreement with AVANT Immunotherapeutics, Inc.
	(if issued upon conversion of another security, clearly identify that other security)
42.	Number and + class of all + securities quoted on ASX (including the securities in clause 38)	Number	+ Class
		255,350,452	Ordinary Fully Paid

⁺ See chapter 19 for defined terms.

Ouotation agreement

• $\mathbf{I}$ *Quotation of our additional *securities is in ASX's absolute discretion. ASX may quote the "securities on any conditions it decides.
• $\overline{2}$ We warrant the following to ASX.
• The issue of the *securities to be quoted complies with the law and is not for $\bullet$ an illegal purpose.
• There is no reason why those *securities should not be granted *quotation.
• An offer of the "securities for sale within 12 months after their issue will not require disclosure under section $707(3)$ or section $1012C(6)$ of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

• Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
• We warrant that if confirmation is required under section 1017F of the Corporations Act in relation to the *securities to be quoted, it has been provided at the time that we request that the "securities be quoted.
• If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the "securities be quoted.

⁺ See chapter 19 for defined terms.

• $\overline{3}$ We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
• $\overline{4}$ We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before *quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

$L f$

Sign here

(Company secretary)

Date: Thursday 19^th April 2007

Print name:

Richard Wadley

$\frac{1}{\frac{1}{1-\frac{1}{1-\frac{1}{1-\frac{1}{1-\frac{1}{1-\frac{1}{1-\frac{1}{1-\frac{1}{1-\frac{1}{1-\frac{1}{1-\frac{1}{1-\frac{1}{1-\frac{1}{1-\frac{1}{1-\frac{1}{1-\frac{1}{1-\frac{1}{1-\frac{1}{1-\frac{1}{1-\frac{1}{1-\frac{1}{1-\frac{1}{1-\frac{1}{1-\frac{1}{1-\frac{1}{1-\frac{1}{1-\frac{1}{1-\frac{1}{1-\frac{1}{1-\frac{1}{1-\frac{1}{1-\frac{1}{1-\frac{1}{1-\frac{1}{1-\frac{1}{1-\frac{1}{$

$+$ See chapter 19 for defined terms.